Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic vinorelbine + cyclophosphamide + capecitabine after CDK4/6 inhibitor progression in HR-positive HER2-negative metastatic breast cancer
2020-003435-13Phase 2Completed
- Sponsor
- Policlinico Gemelli
- Start
- Jun 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vinorelbine, cyclophosphamide and capecitabine in breast cancer, sponsored by Policlinico Gemelli. Primary endpoint: Time to progression. Started Jun 2021; status: completed.
02
Drugs
vinorelbinecyclophosphamidecapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2020-003435-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003435-13.